Impact of CES1 Genotype on Metabolism of Methylphenidate
NCT ID: NCT02147535
Last Updated: 2014-10-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
78 participants
INTERVENTIONAL
2014-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metabolism of Methylphenidate and Enalapril Based on CES1 Genotype
NCT02135263
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
NCT03781752
The Relationship Between CES1 Genotype and Methylphenidate Response in Children With ADHD - INDICES Work Package 6
NCT04366609
Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD
NCT00500071
To Explore the Influence of Appetite Reduction and Medication Effect of Methylphenidate in Patients With Attention-deficit/Hyperactivity Disorder(ADHD) Through Pharmacogenetics.
NCT04006548
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Methylphenidate
Methylphenidate
10 mg as a single dose followed by one blood sample 3 hours post-dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methylphenidate
10 mg as a single dose followed by one blood sample 3 hours post-dose
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Caucasian
Exclusion Criteria
* Pregnancy
* Smoking
* High level of alcohol consumption (\> 21 units per week for men and 14 for women)
* Known allergy towards methylphenidate
* Permanent use of medication (contraception ok)
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Ministry of Science, Technology and Innovation, Denmark
OTHER_GOV
Mental Health Centre Sct. Hans (Denmark)
UNKNOWN
University of Copenhagen
OTHER
The Leiden Academic Center for Drug Research (LACDR)
UNKNOWN
Duke University
OTHER
Bispebjerg Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Claus Stage
M.D.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Claus Stage, M.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Clinical Pharmacology, Bispebjerg University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Clinical Pharmacology, Bispebjerg University Hospital
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INDICES-WP2-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.